SEC Company Response from OnKure Therapeutics, (OKUR) — Apr 30, 2026
OnKure Therapeutics, Inc.
Date: April 30, 2026 · CIK: 0001637715 · Accession: 0001193125-26-197156
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295304
Letter
Re:
OnKure Therapeutics, Inc. 6707 Winchester Circle, Suite 400 Boulder, Colorado 80301 April 30, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards
OnKure Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-295304
Acceleration Request
Requested Date:
May 4, 2026
Requested Time:
4:00 p.m. Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, OnKure Therapeutics, Inc. (the “ Company ”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-295304) (the “ Registration Statement ”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with the Company’s counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Phillip S. McGill at (858) 350-2249. [ Signature page follows ]
Sincerely,
OnKure Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP OnKure Therapeutics, Inc. 6707 Winchester Circle, Suite 400 Boulder, Colorado 80301 April 30, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: OnKure Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-295304 Acceleration Request Requested Date: May 4, 2026 Requested Time: 4:00 p.m. Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, OnKure Therapeutics, Inc. (the “ Company ”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-295304) (the “ Registration Statement ”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with the Company’s counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Phillip S. McGill at (858) 350-2249. [ Signature page follows ] Sincerely, OnKure Therapeutics, Inc. /s/ Nicholas A. Saccomano Nicholas A. Saccomano Chief Executive Officer cc: Phillip S. McGill, Wilson Sonsini Goodrich & Rosati, P.C.